Next Article in Journal
The Prognostic and Therapeutic Implications of the Chemoresistance Gene BIRC5 in Triple-Negative Breast Cancer
Next Article in Special Issue
Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives
Previous Article in Journal
Heterogeneity and Differentiation Trajectories of Infiltrating CD8+ T Cells in Lung Adenocarcinoma
Previous Article in Special Issue
Role of the Hedgehog Pathway and CAXII in Controlling Melanoma Cell Migration and Invasion in Hypoxia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 21
10.3390/cancers14215184
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?

Cancers 2022, 14(21), 5184; https://doi.org/10.3390/cancers14215184
by Hanna H. Kakish 1, Fasih Ali Ahmed 1, Mohamedraed Elshami 1, Alexander W. Loftus 1, Richard S. Hoehn 1, John B. Ammori 1, Lee M. Ocuin 1, Jordan M. Winter 1, Jeremy S. Bordeaux 2, Ankit Mangla 3 and Luke D. Rothermel 1,*
Reviewer 1:
Long Yuan
Reviewer 2: Anonymous
Cancers 2022, 14(21), 5184; https://doi.org/10.3390/cancers14215184
Submission received: 22 September 2022 / Revised: 19 October 2022 / Accepted: 20 October 2022 / Published: 22 October 2022
(This article belongs to the Collection Emerging Therapeutics in Advanced Melanoma)

Round 1

Reviewer 1 Report

1. Overall a clear written manuscript, could you expand more on endpoints and 5-year prognosis rate on each mechanism of treatment so it would be clearer and gives direct view on the treatments.

2. Figure 4, almost all of the mechanisms are covered while need to be more specific on mainstream mechanisms, upstream and downstream signaling proteins should be mentioned and explained. 

3. After MEK-BRAF inhibition there comes anti-PD1 and combination therapy, which is hot topics these days. Give more details via future opportunities on new treatments especially PD1 related treatments in discussion section.

 

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

This review provides an overview of phase 3 clinical trials to explore trends in clinical trials and identify emerging treatments with exploratory mechanisms. The topic of this review is very relevant as a number of drugs and treatment modalities are being investigated to improve the current melanoma therapeutic options. This review describes trends in clinical trials investment in late-stage melanoma and predicts what developments in melanoma treatment can be expected, with a focus on exploratory drug mechanisms. The manuscript is comprehensive and well written.

The review searched nine international clinical trials databases for phase 3 cutaneous melanoma clinical trials since 2010 and found 73 relevant drug therapy trials. The Methods are correctly designed detailed. The strength of Results is that it clearly presents the approved and exploratory studies separately. The Discussion is coherent, and 7 published trials were also reviewed in the manuscript to highlight the promising therapeutic aspects of exploratory drugs.

Great paper in every aspect, accurate and detailed review.  

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop